Vaccines, Vaccination and Immunization

Dr. Byungse Suh is a Professor in Lewis Katz School of Medicine at Department of Microbiology and Immunology, Temple University. Dr. Byungse Suh received his MD, University of Miami and Postdoctoral Fellowship, Biochemistry, University of Iowa. Internship and Residency, Internal Medicine, University of Wisconsin Hospital. He is an Member of Fellow, Infectious Diseases Society of America and American Society for Microbiology.

Dr. Byungse Suh Research interests includes Pharmacokinetics of antimicrobial agents, Drug protein binding in disease states, In vitro determination of drug photo toxicity, Clinical trial studies of antimicrobial agents.

Dr. Igor S. Lukashevich is a Professor in School of Medicine at Department of Pharmacology and Toxicology and Center for Predictive Medicine, University of Louisville. Dr. Lukashevich received his MD degree from Minsk Medical School (Belarus) and PhD and DSc (Doctor of Sciences) Degrees in Virology from Institute of Virology, Academy of Medical Sciences in Moscow (Russia). His post-doctoral training was focused on molecular biology of viral hemorrhagic fevers (CDC, Atlanta, GA, USA; Institute of Tropical Medicine, Antwerp, Belgium; University of Hamburg, Heinrich-Pette Institute of Experimental Virology and Immunology). From 1990-1993 he served as an invited expert on hemorrhagic fever viruses at University of Conakry/IRBAG, Guinea, and as a consultant of German Agency for Technical Cooperation(GTZ). From 2001 till 2011 he served as Assistant, and then Associate Professor in Institute of Human Virology, University of Maryland, Baltimore, MD, USA.

Dr. Igor S. Lukashevich research interest includes molecular biology and pathogenesis of viral hemorrhagic fevers. His current projects mostly focus on innovative approaches in vaccine research and development: rational design of live-attenuated vaccines, recombinant YF17D-based vaccines; advanced alphavirus replicon technology; infectious DNA vaccines; and his target infectious are: Lassa Fever and South American Hemorrhagic Fevers, Chikungunya, Yellow Fever, and Venezuelan Equine Encephalitis.

Professor Frederic Deschamps is a medical doctor since 1990 and he has completed his PhD of toxicology in 1993 at the University of Lille, France. He is the director of the Department of Occupational Health of the Medicine Faculty of Reims, France. He has published more than 40 papers in medical journals about occupational health and diseases.

Flu vaccines, Influenza Vaccines

Maysaa El Sayed Zaki PhD, MD in Clinical Pathology-Clinical Microbiology and Immunology is Professor at Mansoura Faculty of medicine and director of clinical laboratories in Mansoura university children hospital and member of the higher promotion committee for Egyptian universities Professor (Clinical Pathology).Professor Dr Maysaa has over 120 scientific papers and projects either presented or published. She is internationally recognized expert in many areas of advanced medicine including clinical microbiology, diagnosis of infectious diseases, molecular biology, Clinical research and drug discovery.. Recent publications also include books on the use of modern technology in laboratory diagnosis like omics technology and nanomedicine. Dr Maysaa has awarded the university award of Academic Excellence and is a member of Who,s Who for International Executives.

Dr. Maysaa El Sayed Zaki has research interest in Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria.

Dr. Abdulwahab R Hashem Binsadiq was from Department of Botany and Microbiology College of Science, he worked as a Associate Professor of Microbiology, College of Science, King Saud University (1991), at present he is working as a Professor of Microbiology, College of Science King Saud University from 1995 to till date

Environmental Sciences, Microbiology

Dr. Leondios Kostrikis received his BSc degree (Biochemistry) in 1987 as a Fulbright scholar and his Ph.D. (Architectural Studies of Inoviruses) in 1993 from New York University, United States. This was followed by post-doctoral research at the Aaron Diamond AIDS Research Center of Rockefeller University (New York) on the molecular virology of human immunodeficiency virus type 1 (HIV-1). He was a recipient of fellowships from the Elizabeth Glazer Pediatric AIDS Foundation and the Aaron Diamond Foundation. He joined the faculty of the Aaron Diamond AIDS Research Center as a staff investigator in 1998 and the Rockefeller University as an Assistant Professor in 1999. He is currently a Professor in the Department of Biological Sciences at University of Cyprus and he is the Head of the Molecular Virology Laboratory.

Research Interest includes HIV-1 transmission and pathogenesis and how host and viral factors may influence the progression of the disease; studying the mechanisms of drug resistance development during HIV antiretroviral therapy; understanding the implications of natural genetic diversity in efficacy of antiretroviral drugs;

Dr. Kishimoto is the Chief Scientific Officer of Selecta Biosciences, a biotechnology company developing synthetic vaccines based on a novel self-assembling nanoparticle technology. Prior to joining Selecta, he was Vice President of Research at Momenta Pharmaceuticals where he led a multidisciplinary team in advancing both novel and complex generic products. Previously he held leadership positions at Millennium Pharmaceuticals and Boehringer Ingelheim. Dr. Kishimoto has published over 50 peer-reviewed articles, including articles in Nature, Science, Cell, and the New England Journal of Medicine. Dr. Kishimoto received his doctoral degree in Immunology from Harvard University and his post-doctoral training at Stanford University.

Nanoparticle-based vaccines for chronic diseases

Dr.Robin Robinson was appointed in April 2008 as the first director of the Biomedical Advanced Research and Development Authority (BARDA), and Deputy Assistant Secretary in the Office of the Assistant Secretary for Preparedness and Response within HHS. Dr. Robinson previously served from 2004-2008 as the Director for the Influenza & Emerging Disease Program within BARDA and its predecessor agency at HHS. Dr. Robinson was recruited by HHS from the vaccine industry in May 2004 to establish a program with scientific and technical experts to implement the strategic plans and policies for medical countermeasures outlined in the National Strategy for Pandemic Influenza. These measures included development, acquisition and establishment of national medical countermeasure stockpiles, and expansion of domestic manufacturing surge capacities for influenza vaccines, antiviral drugs, rapid diagnostics, and non-pharmaceutical countermeasures including respiratory devices. For his leadership in this role, Dr. Robinson was the recipient of the Department of Defense’s Clay Dalrymple Award in 2008 and a finalist for the Service to America Medal in 2009. Dr. Robinson received a Bachelor’s degree in Biology from Millsaps College in 1976, a Doctoral degree from the University of Mississippi Medical School in medical microbiology, and completed in 1983 a NIH postdoctoral fellowship with the State University of New York at Stony Brook in molecular oncology. As Director of Vaccines at Novavax, Inc., he developed patented platform vaccine technologies including virus-like particles and subunit protein vaccines for human pathogens including malaria, human papilloma, hepatitis, and influenza and for prostate, melanoma, and cervical cancers. Dr. Robinson also serves on World Health Organization (WHO) international expert teams on pandemic influenza vaccines. Additionally, he continues to serve as an editorial board member and reviewer for several professional scientific and technical journals on virology, vaccines, public health, and biotechnology.

U.S. Department of Health and Human Services (HHS)
USA
U.S. Department of Health and Human Services (HHS), USA

He had his D.V.M. education at Jiangxi Agricultural University and my M.S. degree (Co-advisors: Professors Zhongzhi Zhang and Hanchun Yang) in Infectious Diseases and Veterinary Preventive Medicine at China Agricultural University in China. He obtained his professional assistant veterinarian license during his two-year employment at Beijing Xijiao Livestock and Poultry Company, Beijing, China. His training in Brucella research started in 1996 in Dr. Gerhardt Schurig’s immunology laboratory at the Virginia Polytechnic Institute and State University (Virginia Tech). He obtained his Ph.D. in Dr. Schurig\\\\\\\'s lab in 2000. He then worked in the same lab as a postdoc for half a year. He obtained his M.S. degree (research advisor: Dr. Pedro Mendes) in computer science in Virginia Tech with a focus on bioinformatics in May 2002. After graduation he worked as a senior research associate for three years in Dr. Bruno Sobral’s group at the Virginia Bioinformatics Institute (VBI). He joined UM in July 2005 as an assistant professor and became an associate professor in September 2011 (with tenure).

Brucella vaccine development,Brucella pathogenesis, Comparative genomics, and Ontology development.

Macaulay A.C. Onuigbo is an Associate Professor in Medicine - College of Medicine, Mayo Clinic Regional Director - Mayo Health System Practice-Based Research Network, Vice Chairman - Department of Nephrology, Luther Midelfort Mayo Health System MacMillan Management Scholar Award -  Mayo Clinic Fellow of the American Society of Nephrology (FASN), Fellow of the West African College of Physicians (FWACP) Editorial board member/reviewer of reputable journals, including Editorial Board member, Quarterly Journal of Medicine. Over 80 publications in print two book chapters NEW DISCOVERIES: Described two new syndromes – late-onset renal failure from angiotensin blockade (LORFFAB) and syndrome of rapid-onset end-stage renal disease (SORO-ESRD).

Hepatitis B in Hemodialysis patients RAAS blockade and kidney function The natural history of CKD Diabetic nephropathy Hypertension Viral infections in Transplantation Acute renal failure Reno-prevention strategies Intra-dialytic hypotension End-stage renal disease Statistics in medical publications Typhoid fever, malaria and FUO Anemia in CKD.

Shiladitya DasSarma is a Professor in the Department of Microbiology & Immunology in the University of Maryland School of Medicine and in the Institute of Marine & Environmental Technology, University System of Maryland, Baltimore, Maryland.  He received his PhD from the Massachusetts Institute of Technology and did his postdoctoral training in the Massachusetts General Hospital, Harvard Medical School.

Use of biological Nanoparticles for antigen delivery and vaccines. Novel approaches to the development of vaccines and vaccination.

Dr. Shirwan is \"Dr. Michael and Joan Hamilton Endowed Chair\" in Autoimmune Disease Professor of Microbiology and Immunology and the Director of the Molecular Immunomodulation Program at the Institute for Cellular Therapeutics. He conducted his graduate studies at the University of California in Santa Barbara CA and postdoctoral studies at California Institute of Technology in Pasadena CA. He joined the University of Louisville in 1998 after holding academic appointments at various institutions in the United States. Dr. Shirwans research focuses on the modulation of immune system for the treatment of immune based diseases with particular focus on type 1 diabetes transplantation and development of vaccines against infections and cancer. Dr. Shirwan is widely published lectured at various National/International conferences served on various federal and nonprofit funding agencies and is on the Editorial Board of nine scientific journals He is a member of several National and International societies and recipient of various awards.

Transplantation Tolerance, Transplantation Immunology, Type 1 diabetes, Prophylactic Vaccines, Therapeutic Vaccines, and Cancer Immunology

Dr. Trilochan Mukkur has received his PhD from the University of Florida, USA. Currently he is working as an Associate Professor in School of Biomedical Sciences, Curtin University, Australia. Dr. Mukkur was a Senior Principal Research Scientist in the CSIRO, Division of Animal Health prior to joining the university sector at the University of Southern Queensland [USQ] where he was a Professorial Fellow at the USQ funded by a private biotechnology company prior to moving to Curtin University. He has a total of well over 90 publications mostly in refereed international journals or monographs. Dr. Mukkur has conducted collaborative research at Stanford University School of Medicine, California, Washington University in St Louis, Missouri, and the laboratory of Cell and Molecular Biology at the Lahey Clinic and Medical Centre in Boston, USA. His research is multidisciplinary involving application of medical microbiology, Prokaryotic molecular genetics, immunology, proteomics and biotechnology. He is a Fellow of the Australian Society of Microbiology [FASM].

Human and animal infectious diseases, rational vaccine biotechnologies Complementary medicinal plants as immunomodulators Nutritional immunology.

He have done his BS Zoology (Hons.) from Delhi University, India, MS Biotechnology from A M University, India and Ph.D. from AIIMS, India. He was the Post-Doctoral fellow at Indiana University-Purdue University from 1998 to 2003.

Viral Therapeutics, Vaccines, and Infectious Diseases

Graham has a master degree in Biophysics from King’s College London and an MBA. Working first in “big Pharma” then as a partner in the Pharmaceutical & Biotechnology Practice of PA Consulting, he returned to industry as VP, Strategic Product Management, SmithKline Beecham, then Head of Executive Decision Support, GSK R&D and most recently VP, Strategy & Business Development, GE Healthcare Biosciences. Graham joined the Board of ImmunoBiology as a non-executive director soon after its formation and was subsequently appointed its CEO in 2006

ImmunoBiology Ltd
UK
ImmunoBiology Ltd, UK

Dr. Xiao-Qing Wei graduated with a medical degree in Medical School of Peking University in Beijing, China. He has completed his PhD in Immunology Department of University of Glasgow and studied the role of cytokine, IL-15, IL-18 and IL-35 in infection and immunity as a research fellow in University of Glasgow in UK. He is a lecturer in Immunology in Cardiff University currently. He has published 60 papers in reputed journals and serving as an editorial board member of some immunology journals. He has awarded honorary professorships in 4 medical universities in China and currently working closely with his collaborators in China and UK in cytokine and skin DC research

My research has focused on understanding the role of some important pro-inflammatory cytokines, such as IL-15, IL-18 and IL-12 family cytokines (IL-23, 27) in the disease process in order to find practical ways to regulate the function of those cytokines for disease treatment.